



# Optimizing active case-finding for tuberculosis

Implementation lessons from South-East Asia



# **Optimizing active case-finding for tuberculosis**

Implementation lessons from South-East Asia

Optimizing active case-finding for tuberculosis: Implementation lessons from South-East Asia

ISBN: 978-92-9022-848-6

© **World Health Organization 2021**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition."

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Optimizing active case-finding for tuberculosis: Implementation lessons from South-East Asia. New Delhi: World Health Organization, Regional Office for South-East Asia; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

# Contents

Foreword	<b>v</b>
Acknowledgements	<b>vi</b>
Abbreviations and acronyms	<b>vii</b>
Glossary of terms	<b>ix</b>
Executive summary	<b>xi</b>
1. Background	<b>1</b>
2. Methodology	<b>5</b>
3. Results	<b>9</b>
A. Population groups, algorithms used and implementation of ACF	<b>10</b>
B. Advantages of ACF	<b>20</b>
C. Treatment outcomes of patients identified by ACF	<b>21</b>
D. Implementation lessons	<b>22</b>
E. Costs of ACF	<b>29</b>
4. Discussion	<b>33</b>
A. Choice of algorithms	<b>34</b>
B. Population groups	<b>34</b>
C. Factors that influence the guidance for planning or implementation of ACF	<b>41</b>
D. Advantages of ACF and its cost-effectiveness	<b>43</b>
E. Treatment outcomes	<b>43</b>
F. Considerations for ACF	<b>44</b>
5. Monitoring of ACF activities	<b>45</b>
6. Recommendations for implementing ACF	<b>47</b>
7. Limitations	<b>51</b>
Annexures	<b>54</b>
References	<b>71</b>



# Foreword



More than 4.3 million people in the WHO South-East Asia Region are estimated to have contracted TB in 2019, of which around 78% have been provided quality TB care. The Region has in recent years made substantial progress in increasing access to quality TB services, with the goal of ensuring at least 90% of TB patients complete TB treatment. Despite Regionwide efforts to maintain TB services throughout the COVID-19 response, the Region has recorded a 20–40% drop in TB notification in 2020.

All countries in the Region are committed to ending TB by or before 2030, which is one of the Region's eight Flagship Priorities. To catch up and reclaim the advantage against TB, countries must detect more cases and detect them early. Prevalence surveys in the Region and beyond show that a substantial proportion of TB patients may not visit a health facility because of no or mild symptoms. Without outreach efforts, vulnerable populations and marginalized groups may never be reached.

Active case-finding (ACF) will help minimize avoidable delays in diagnosis and initiation of treatment and will reduce the risk of unfavourable treatment outcomes, health sequelae, and adverse social and economic consequences. Active screening reduces TB transmission in a household, workplace, school or other community setting by removing people with prevalent disease and shortening the duration of infectiousness. When active screening is combined with appropriate diagnostic testing, policy-makers can enhance the uptake of TB preventive treatment (TPT) for people without TB disease, but who are at risk of progression.

Implementing ACF is expensive. However, if carefully planned and implemented, it will be cost effective and will support last mile efforts to reduce TB incidence. When used in conjunction with the 2021 WHO guidelines on systematic screening for tuberculosis disease, this publication – which is based on a review of publications on ACF from across the Region, in addition to several countries with similar settings – will help Member States plan and monitor ACF activities. I urge all stakeholders to appropriately leverage and apply the information contained herein, as together we continue to drive rapid and sustained progress towards the TB-free Region and world to which we are committed.

A handwritten signature in black ink, which appears to read 'Poonam Khetrpal Singh'.

Dr Poonam Khetrpal Singh  
Regional Director  
WHO South-East Asia Region

# Acknowledgements

Work on this document, titled “Optimizing active case-finding for tuberculosis: implementation lessons from South-East Asia”, has been led by Dr Alka Aggarwal Singh, consultant with the WHO Regional Office. The document was peer-reviewed by Dr Jacob Creswell, focal point for TB REACH projects in the Stop TB Partnership, Geneva; Dr Jamie Tonsing, Regional Director, The Union’s South-East Asia Office, Delhi; and Dr Vineet Chadha, Senior Epidemiologist, National Tuberculosis Institute, Bangalore. Feedback on the document was provided by the national TB programmes of Bhutan, Nepal and Sri Lanka. All WHO country offices in the Region also contributed to the development of this document.

We acknowledge the role of the staff of the TB unit of the WHO Regional Office for South-East Asia in bringing out this publication, under the overall guidance of Dr Tjandra Yoga Aditama, Acting Director for Communicable Diseases at the Regional Office. We also acknowledge the role of the Reports and Documentation Unit in the Regional Office for editing the manuscript.

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report?>